

Completion of capital increase in Initiator Pharma

Initiator Pharma A/S (“Initiator” or the “Company”) has today completed the capital increase directed at members of executive management and key management under the long term incentive program for 2023 (“LTI2023-program”), which was announced on 14 October 2024.

Today, the Company’s share capital has been increased by a total nominal amount of DKK 11,392.50, divided into 108,500 shares (the “New Shares”), as a result of a share issue to certain members of executive management and key management under the LTI2023 program.

The capital increase in connection with the subscription of New Shares by certain members of executive management and key management amounted to a nominal value of DKK 11,392.50, corresponding to 108,500 shares with a nominal value of DKK 0.105 each. The 108,500 New Shares were subscribed for by cash contribution at a price of DKK 0.105 per share, and as a result, the Company’s gross proceeds amount to a total of DKK 11,392.50.

The New Shares are subject to the same rights as existing shares under the Company’s articles of association and are expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872.

After the completion of the capital increase, the total nominal share capital of the company is DKK 5,896,627.905, divided into 56,158,361 shares with a nominal value of DKK 0.105 each, corresponding to 56,158,361 votes.

The Company’s updated articles of association are now available on the Company’s website, following registration with the Danish Business Authority.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and two preclinical assets. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Completion of capital increase in Initiator Pharma